PL Lodz Watala C: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
|country=Poland | |country=Poland | ||
|weblink=[http://www.flawopiryna.pl/ flawopiryna] | |weblink=[http://www.flawopiryna.pl/ flawopiryna] | ||
|MiPNetLab=Watala C, Labieniec M, Siewiera K | |MiPNetLab=Watala C, Labieniec M, Dudzinska D, Novak J, Siewiera K | ||
|info=[[IOC61]], [http://www.oroboros.at/?IOC55-56 IOC55-56] | |info=[[IOC61]], [http://www.oroboros.at/?IOC55-56 IOC55-56] | ||
}} | }} | ||
Revision as of 16:24, 28 October 2012
- Mitochondrial respiratory capacity under normal and pathophysiological conditions (diabetes mellitus, atherothrombosis, brain-blood barrier disruption, cancerogenesis)
- Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity
- Targeting of biochemical and molecular burden of diabetes
